# US 2014/0235615 A1 · Heterocyclic compound

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0235615 A1
- Document ID: US20140235615A1
- Status: Published application
- Kind: A1
- Application number: 14/223,329
- Filed: 2014-03-24
- Published: 2014-08-21
- Earliest claimed: 2010-02-17
- Assignees: Takeda Pharmaceutical Company Limited
- Applicants: Takeda Pharmaceutical Company Limited
- Inventors: Misaki HOMMA; Toru MIYAZAKI; Yuya OGURO; Osamu KURASAWA
- Web page: https://patentgrep.com/patent/US20140235615A1

## CPC

- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/541: Non-condensed thiazines containing further heterocyclic rings
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 495/04: Ortho-condensed systems
- C07D 498/20: Spiro-condensed systems
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Provided is a compound useful for the prophylaxis or treatment of cancer. The present invention relates to a compound represented by formula (I): wherein each symbol in the formula is as defined in the specification, or a salt thereof or a prodrug thereof, which is useful for the prophylaxis or treatment of cancer.

## Claims

### Claim at position 1

1-31. (canceled)

### Claim 32

The compound
or a salt thereof.

### Claim 33 (depends on 32)

A medicament comprising the compound according to claim 32, or a salt thereof.

### Claim 34 (depends on 33)

The medicament according to claim 33, which is a cell division cycle 7 inhibitor.

### Claim 35 (depends on 33)

The medicament according to claim 33, which is an agent for the treatment of cancer, wherein said cancer is mediated by cell division cycle 7.

### Claim 36 (depends on 32)

A method of inhibiting a cell division cycle 7 in a mammal, which comprises administering an effective amount of the compound according to claim 32, or a salt thereof to the mammal.

### Claim 37 (depends on 32)

A method for the treatment of cancer in a mammal, wherein said cancer is mediated by cell division cycle 7, which comprises administering an effective amount of the compound according to claim 32, or a salt thereof to the mammal.

### Claim 38 (depends on 32)

The compound according to claim 32, wherein the compound is a tautomer isomer represented by the partial structure of the formula:
where R1 is methyl at the 5-position, or a salt thereof.

### Claim 39 (depends on 32)

The compound according to claim 32, wherein the compound is a tautomer isomer represented by the partial structure of the formula:
where R1 is methyl at the 3-position, or a salt thereof.

### Claim 40 (depends on 32)

The compound according to claim 32, wherein the compound or a salt thereof is a hydrate.
